Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Cysic Cysic +20.83%
#4 Bedrock Bedrock +18.46%
#5 Nockchain Nockchain +16.07%
#6 Velvet Velvet +14.00%
#7 Fabric Protocol Fabric Protocol +13.90%
#8 Perle Perle +12.76%
#9 Starpower Starpower +12.51%
#10 Nillion Nillion +12.50%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
AXIM Biotechnologies, Inc. AXIM Biotechnologies, Inc.

AXIM Biotechnologies, Inc.

AXIM
Rank in Stocks #37613
AXIM Biotechnologies, Inc. specializes in the creation and distribution of... AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.
Share Price
$0.0046
Last synced: 2026-08-14
Market Cap
$1.57M
Change (1 day)
-8.00%
Change (1 year)
-9.80%
Country
US
Trade AXIM Biotechnologies, Inc. (AXIM)

Category

Healthcare
P/E ratio for AXIM Biotechnologies, Inc. (AXIM)
P/E ratio as of 2026 TTM: 0
According to AXIM Biotechnologies, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for AXIM Biotechnologies, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.